Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
Katharina Wagner, Frederik Damm, Gudrun Göhring, et al.
European Journal of Haematology
|
June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
Christian Straka, Stefan Knop, Martin Vogel, et al.
Lancet (London, England)
|
February 26, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, et al.
Haematologica
|
January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Elias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
British Journal of Haematology
|
December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Ulrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Blood
|
May 7, 2014
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Michela Tassara, Konstanze Döhner, Peter Brossart, et al.
Cancer Research Communications
|
June 4, 2026
CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
Claire Roddie, William Day, Meera Raymond, et al.
Nature Medicine
|
November 11, 2024
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
Kate Cwynarski, Gloria Iacoboni, Eleni Tholouli, et al.
Haematologica
|
January 5, 2023
Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
Christoph Rummelt, Olga Grishina, Claudia Schmoor, et al.
Blood
|
February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
Claire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
Katharina Wagner, Frederik Damm, Gudrun Göhring, et al.
European Journal of Haematology
|
June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
Christian Straka, Stefan Knop, Martin Vogel, et al.
Lancet (London, England)
|
February 26, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, et al.
Haematologica
|
January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Elias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
British Journal of Haematology
|
December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Ulrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Blood
|
May 7, 2014
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Michela Tassara, Konstanze Döhner, Peter Brossart, et al.
Cancer Research Communications
|
June 4, 2026
CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
Claire Roddie, William Day, Meera Raymond, et al.
Nature Medicine
|
November 11, 2024
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
Kate Cwynarski, Gloria Iacoboni, Eleni Tholouli, et al.
Haematologica
|
January 5, 2023
Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
Christoph Rummelt, Olga Grishina, Claudia Schmoor, et al.
Blood
|
February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
Claire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Page
of 6